SOHO 2023

Karun Neupane, MDVideo Insights | September 22, 2023
Karun Neupane, MD, discusses why the meeting was a valuable experience for him as a first-time attendee.
View More
Advertisement
Leah LawrenceMeeting News | September 19, 2023
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
Leah LawrenceMyelofibrosis | September 19, 2023
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
Chadi Nabhan, MD, MBA, FACPMeeting News | September 14, 2023
Dr. de Lima discusses progress and remaining challenges with allogeneic CAR-T and other cellular therapy products.
Advertisement
Swaminathan Iyer, MDVideo Insights | September 14, 2023
Swaminathan Iyer, MD, joins Chadi Nabhan, MD, MBA, FACP, to discuss advances in T-cell lymphoma.
Alessandra Ferrajoli, MDMeeting News | September 14, 2023
Alessandra Ferrajoli, MD, discusses her presentation on the topic during the Eleventh Annual Meeting of SOHO.
Mary Ann Anderson, MBBS, PhDMeeting News | September 13, 2023
Dr. Anderson spoke about her plenary session on the topic at the Eleventh Annual Meeting of SOHO.
Cecilia BrownChronic Lymphocytic Leukemia | September 11, 2023
All patients included in the study required treatment and had not previously received psychiatric treatment.
Cecilia BrownMeeting News | September 11, 2023
The study included patients with relapsed or refractory B-cell malignancies who were in the phase I/II BRUIN trial.
Cecilia BrownChronic Lymphocytic Leukemia | September 11, 2023
The researchers investigated if iso-cel in patients with relapsed or refractory CLL is a cost-efficient option.
Cailin ConnerMeeting News | September 10, 2023
Noteworthy regional disparities were noticed in treatment strategies.
Loretta Nastoupil, MDMeeting News | September 10, 2023
The phase II study evaluated liso-cel in patients with relapsed or refractory follicular lymphoma.
Cailin ConnerChronic Lymphocytic Leukemia | September 10, 2023
Investigators from the Mayo Clinic identified 145 patients with CLL who were treated between 2014-2021.
Leah LawrenceMantle Cell Lymphoma | September 10, 2023
Achieving event-free survival at 24 months using modern treatments was associated with improved OS.
Leah LawrenceMeeting News | September 10, 2023
Intratumoral hypoxia could be associated with CAR-T outcomes in patients with non-Hodgkin lymphoma.
Leah LawrenceMeeting News | September 10, 2023
The composition of T cells in patients with sMZL may affect the efficacy of T-cell-based therapies.
Cailin ConnerMeeting News | September 10, 2023
The need for phlebotomies substantially decreased in those who received ruxolitinib after hydroxyurea.
Cailin ConnerMeeting News | September 10, 2023
The combined average cost for the index hospitalization and two-year TE-related readmissions was $30,285.
Cecilia BrownMeeting News | September 9, 2023
Patients with MPNs faced higher direct and indirect costs and were significantly more likely to take disability leave.
Cailin ConnerPolycythemia Vera | September 9, 2023
The investigators sought to investigate the diagnostic landscape of polycythemia vera in LMICs.
Advertisement
Advertisement
Editorial Board